Smith & Nephew plc
NYSE:SNNMedical - Devices
-$0.43 today
- Market cap
- $12.72B
- Beta
- 0.67
- P/E (TTM)
- 20.1
- EPS (TTM)
- $0.74
- Dividend yield
- 2.59%
Volume 1.22M
Average 1.10M
SNN Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Smith & Nephew plcNYSE: SNN
Stock-Based Compensation · Q4 FY2025 · quarter ended Dec 2025
Stock-based compensation grows 10.0% year over year
Q4 FY2025 stock-based compensation of $22M rose 10.0% year over year. Over 3 fiscal years it compounded at +2.4% a year.
Context
- Stock-based compensation amounted to 0.7% of revenue in FY2025, unchanged from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 43M USD
- Year-over-year change
- +7.5%
- 4-year CAGR
- +1.2%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 43M | +7.5% |
| FY2024 | 2024-12-31 | 40M | +2.6% |
| FY2023 | 2023-12-31 | 39M | -2.5% |
| FY2022 | 2022-12-31 | 40M | -2.4% |
| FY2021 | 2021-12-31 | 41M | — |
Stock-Based Compensation vs competitors
How SNN compares with its peers on the latest reported figures
- SNN's FY2025 stock-based compensation of $43M is the 5th largest of the 11 companies compared; the peer median is $34.28M.
- Its year-over-year change of +7.5% is the 5th highest of 11, against a peer median of +1.0%.
- Stock-based compensation amounts to 0.7% of revenue for SNN, versus a peer median of 1.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $251M | +9.6% | +13.1% | 1.0% | |
| LTM Jun 2026 | $98.2M | +13.7% | -4.9% | 1.2% | |
| LTM Mar 2026 | $75.06M | -4.1% | +22.0% | 9.5% | |
| LTM Jun 2026 | $48.96M | -3.9% | +14.9% | 1.6% | |
| FY2025 | $43M | +7.5% | +2.4% | 0.7% | |
| LTM Mar 2026 | $42.3M | +40.4% | +15.9% | 5.1% | |
| LTM Apr 2026 | $26.26M | -14.3% | -5.5% | 1.2% | |
| LTM Mar 2026 | $21.88M | +6.0% | -12.5% | 1.3% | |
| LTM Mar 2026 | $19.96M | -39.8% | +9.2% | 1.5% | |
| LTM Mar 2026 | $17.9M | +22.5% | +38.6% | 7.4% | |
| LTM Mar 2026 | $2.88M | -27.4% | +5.5% | 2.4% | |
| Peer median (excluding SNN) | $34.28M | +1.0% | +11.2% | 1.5% | |
Competitors are the stored peer set for SNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 524M | 223M | 263M | 412M | 625M |
| Depreciation & Amortization | 563M | 548M | 527M | 555M | 573M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 41M | 40M | 39M | 40M | 43M |
| Change in Working Capital | (232M) | (510M) | (227M) | (123M) | 33M |
| Accounts Receivables | (81M) | (103M) | (49M) | (81M) | (175M) |
| Inventory | (151M) | (407M) | (178M) | (42M) | 208M |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | (19M) | 167M | 6M | 103M | 11M |
| Operating Cash Flow | 877M | 468M | 608M | 987M | 1.29B |
| Capital Expenditures | (408M) | (358M) | (427M) | (381M) | (433M) |
| Acquisitions (Net) | (285M) | (113M) | (21M) | (186M) | (9M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 2M | (1M) | 0 | (2M) | 36M |
| Investing Cash Flow | (691M) | (472M) | (448M) | (569M) | (406M) |
| Debt Repayment | (59M) | (43M) | (52M) | 945M | (140M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | (158M) | 0 | 0 | (502M) |
| Dividends Paid | (329M) | (327M) | (327M) | (327M) | (330M) |
| Other Financing Activities | (257M) | (398M) | 179M | (704M) | 17M |
| Financing Cash Flow | (645M) | (926M) | (200M) | (86M) | (955M) |
| Effect of Forex Changes | (7M) | (11M) | (4M) | (15M) | 14.18M |
| Net Change in Cash | (466M) | (941M) | (44M) | 317M | (62M) |
| Free Cash Flow | 469M | 110M | 181M | 606M | 852M |
Smith & Nephew plc
NYSE:SNN
Intrinsic Alpha fair value
Locked
Current Price
$30.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.